Real-World Experience of Niraparib as Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer: A Single-Center Retrospective Study
In the real-world setting, the use of niraparib as a maintenance treatment for newly diagnosed advanced ovarian cancer has been shown to be effective and well tolerated, which is consistent with the results of previous randomized Phase III trials.
Authors
- Huijuan Wu (ORCID: https://orcid.org/0000-0003-4681-4440)
- Lewen Bao
- Yaomei Ma
- Xin Fu (ORCID: https://orcid.org/0009-0001-7478-0244)
- Ying Chen (ORCID: https://orcid.org/0000-0002-8884-3138)
- Ke Wang (ORCID: https://orcid.org/0000-0002-3003-5605)
- Wenxin Liu (ORCID: https://orcid.org/0000-0002-3869-6520)
- Li Zhang (ORCID: https://orcid.org/0000-0003-1135-8262)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- OncoTargets and Therapy
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/ott.s528382
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Society for Medical Oncology